Carl Zeiss Meditec AG AFX
XETR · Germany · Health Technology
€31.24-0.04 (-0.13%)
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
ZEISS Medical Technology, one of the world's leading medical technology companies, announced expansive developments across its comprehensive ZEISS Retina Workflow at the European Society of Retina Specialists (EURETINA) congress, spanning retinal imaging, surgical visualization, digital workflow technologies and vitreoretinal surgery. The innovations further strengthen ZEISS's ability to support eye care professionals and retina specialists across the continuum of retinal care, from diagnosis an
Carl Zeiss Meditec has seen its share price fall sharply in recent years, which puts the spotlight firmly on whether the current valuation is still supported by its earnings. For anyone following the stock, the key issue now is how much of that setback is already reflected in what the market is willing to pay for each euro of profit. The share price has declined 80.6% over the past 5 years, which raises the question of how investors are now weighing the business against its earnings...
Carl Zeiss Meditec (XTRA:AFX) heads into the Berenberg and Goldman Sachs 15th German Corporate Conference on 23 September with investors watching how management frames recent share performance and underlying medical technology trends. Carl Zeiss Meditec’s share price has slipped over recent months, with a 30 day share price return of down 9.11% and a year to date share price return of down 25.49%. The 1 year total shareholder return of down 34.30% points to longer running pressure on...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.